IN2014MN02487A - - Google Patents
Info
- Publication number
- IN2014MN02487A IN2014MN02487A IN2487MUN2014A IN2014MN02487A IN 2014MN02487 A IN2014MN02487 A IN 2014MN02487A IN 2487MUN2014 A IN2487MUN2014 A IN 2487MUN2014A IN 2014MN02487 A IN2014MN02487 A IN 2014MN02487A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical composition
- adhesive free
- present
- excipient
- granular
- Prior art date
Links
- 239000000853 adhesive Substances 0.000 abstract 3
- 230000001070 adhesive effect Effects 0.000 abstract 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229960000980 entecavir Drugs 0.000 abstract 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2779052 CA2779052A1 (en) | 2012-05-31 | 2012-05-31 | Pharmaceutical composition of entecavir and process of manufacturing |
| PCT/CA2013/000517 WO2013177672A1 (en) | 2012-05-31 | 2013-05-28 | Pharmaceutical composition of entecavir and process of manufacturing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02487A true IN2014MN02487A (https=) | 2015-07-17 |
Family
ID=49672225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2487MUN2014 IN2014MN02487A (https=) | 2012-05-31 | 2013-05-28 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150110869A1 (https=) |
| EP (1) | EP2854773B1 (https=) |
| JP (1) | JP6320371B2 (https=) |
| KR (1) | KR20150015500A (https=) |
| CN (1) | CN104363896A (https=) |
| CA (2) | CA2779052A1 (https=) |
| HK (1) | HK1208620A1 (https=) |
| IN (1) | IN2014MN02487A (https=) |
| WO (1) | WO2013177672A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY185605A (en) * | 2014-06-20 | 2021-05-25 | Ctc Bio Inc | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor |
| CN104473896B (zh) * | 2014-12-01 | 2017-04-19 | 东莞市金美济药业有限公司 | 一种快速崩解的拉米夫定片及其制备工艺 |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| CN109550020A (zh) * | 2019-02-14 | 2019-04-02 | 任连智 | 一种治疗乙肝大小三阳的药物制剂及制备方法 |
| CN110354129A (zh) * | 2019-08-19 | 2019-10-22 | 苏州扬厉医药科技有限公司 | 一种治疗乙肝病毒的新药药物组合及制备方法 |
| CN117440800A (zh) * | 2021-06-07 | 2024-01-23 | R·P·舍勒科技有限责任公司 | 用于对水分敏感的药物组合物的保护性包衣 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064221A1 (en) * | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Co. | Low dose entecavir formulation and use |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| WO2004000265A2 (en) * | 2002-06-24 | 2003-12-31 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US7905852B2 (en) * | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
| US20070281000A1 (en) * | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
| CN101245068A (zh) * | 2007-02-14 | 2008-08-20 | 浙江医药股份有限公司新昌制药厂 | 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途 |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| EP2467144A1 (en) * | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
| EA201290556A1 (ru) * | 2009-12-23 | 2013-01-30 | Рациофарм Гмбх | Оральная лекарственная форма, включающая энтекавир |
| JP2014500261A (ja) * | 2010-11-19 | 2014-01-09 | ギリアード サイエンシーズ， インコーポレイテッド | リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 |
| EP2508172A1 (en) * | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Stable and uniform formulations of entecavir and preparation method thereof |
| EP2780001A4 (en) * | 2011-11-14 | 2015-10-28 | Hetero Research Foundation | SOLID ORAL ENTECAVIR COMPOSITIONS WITH FAST RELEASE |
| WO2013114389A1 (en) * | 2011-12-21 | 2013-08-08 | Mylan Laboratories Limited. | Process for preparing solid oral formulations comprising low dose of entecavir |
-
2012
- 2012-05-31 CA CA 2779052 patent/CA2779052A1/en not_active Abandoned
-
2013
- 2013-05-28 US US14/404,176 patent/US20150110869A1/en not_active Abandoned
- 2013-05-28 EP EP13797878.9A patent/EP2854773B1/en active Active
- 2013-05-28 WO PCT/CA2013/000517 patent/WO2013177672A1/en not_active Ceased
- 2013-05-28 KR KR20147034899A patent/KR20150015500A/ko not_active Ceased
- 2013-05-28 HK HK15109146.7A patent/HK1208620A1/xx unknown
- 2013-05-28 CN CN201380030696.6A patent/CN104363896A/zh active Pending
- 2013-05-28 CA CA2874779A patent/CA2874779C/en active Active
- 2013-05-28 JP JP2015514297A patent/JP6320371B2/ja active Active
- 2013-05-28 IN IN2487MUN2014 patent/IN2014MN02487A/en unknown
-
2018
- 2018-04-03 US US15/944,452 patent/US20190076366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2874779C (en) | 2019-03-05 |
| CN104363896A (zh) | 2015-02-18 |
| EP2854773A1 (en) | 2015-04-08 |
| CA2874779A1 (en) | 2013-12-05 |
| US20150110869A1 (en) | 2015-04-23 |
| US20190076366A1 (en) | 2019-03-14 |
| HK1208620A1 (en) | 2016-03-11 |
| JP6320371B2 (ja) | 2018-05-09 |
| CA2779052A1 (en) | 2013-11-30 |
| WO2013177672A1 (en) | 2013-12-05 |
| EP2854773B1 (en) | 2020-05-06 |
| KR20150015500A (ko) | 2015-02-10 |
| JP2015521191A (ja) | 2015-07-27 |
| EP2854773A4 (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02487A (https=) | ||
| AU2018256602A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| WO2011106729A3 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| MD4736B1 (ro) | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia | |
| WO2013147649A3 (ru) | ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ | |
| MX2013001757A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| PH12012502083A1 (en) | Manufacturing of active-free granules and tablets comprising the same | |
| MY152951A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| TR201310724A2 (tr) | Linagliptinin farmasotik formulasyonları. | |
| GR1008821B (el) | Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| EP2593460A4 (en) | 7,9-NITROGEN-RADIKAL-4-OXO-4H-PYRIDO- [L, 2-A-] PYRIMIDIN-2-CARBOXYLIC ACID BENZYLAMIDE VIROSTATIKA | |
| LT3882244T (lt) | Junginys, farmaciniu požiūriu priimtina jo druska arba optinis jo izomeras, jo gamybos būdas, farmacinė kompozicija, kurios sudėtyje jis yra kaip veiklioji sudedamoji dalis, skirta virusinių ligų profilaktikai arba gydymui | |
| IN2011CH03893A (https=) | ||
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease | |
| IN2013CH05288A (https=) |